ID   BxPC-3
AC   CVCL_0186
SY   BxPc-3; BXPC-3; Bx-PC3; BXPC3; BxPC3; BxPc3; Biopsy xenograft of Pancreatic Carcinoma line-3
DR   BTO; BTO:0001861
DR   CLO; CLO_0002065
DR   EFO; EFO_0002709
DR   MCCL; MCC:0000077
DR   CLDB; cl516
DR   CLDB; cl517
DR   CLDB; cl518
DR   AddexBio; C0018003/27
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1687
DR   BCRC; 60283
DR   BCRJ; 0056
DR   BioSample; SAMN03470942
DR   BioSample; SAMN10987955
DR   CCRID; 3111C0001CCC000274
DR   CCRID; 3131C0001000700012
DR   Cell_Model_Passport; SIDM00132
DR   CGH-DB; 161-1
DR   CGH-DB; 9272-4
DR   ChEMBL-Cells; CHEMBL3307637
DR   ChEMBL-Targets; CHEMBL614530
DR   Cosmic; 707248
DR   Cosmic; 730531
DR   Cosmic; 736269
DR   Cosmic; 755301
DR   Cosmic; 808164
DR   Cosmic; 872995
DR   Cosmic; 906693
DR   Cosmic; 913310
DR   Cosmic; 918055
DR   Cosmic; 922251
DR   Cosmic; 923165
DR   Cosmic; 932515
DR   Cosmic; 933516
DR   Cosmic; 947403
DR   Cosmic; 948372
DR   Cosmic; 949321
DR   Cosmic; 968108
DR   Cosmic; 1006369
DR   Cosmic; 1198209
DR   Cosmic; 1299295
DR   Cosmic; 1366281
DR   Cosmic; 1477430
DR   Cosmic; 1518232
DR   Cosmic; 1534316
DR   Cosmic; 1571773
DR   Cosmic; 1644317
DR   Cosmic; 1768263
DR   Cosmic; 1945873
DR   Cosmic; 2434095
DR   Cosmic-CLP; 906693
DR   DepMap; ACH-000535
DR   DSMZ; ACC-760
DR   ECACC; 93120816
DR   GDSC; 906693
DR   GEO; GSM206447
DR   GEO; GSM621894
DR   GEO; GSM784699
DR   GEO; GSM886896
DR   GEO; GSM887961
DR   GEO; GSM1024397
DR   GEO; GSM1374415
DR   GEO; GSM1374416
DR   GEO; GSM1374417
DR   GEO; GSM1588608
DR   GEO; GSM1588620
DR   GEO; GSM1669634
DR   IARC_TP53; 312
DR   ICLC; HTL96011
DR   KCB; KCB 200428YJ
DR   LiGeA; CCLE_491
DR   Lonza; 1013
DR   PRIDE; PXD003198
DR   TOKU-E; 707
DR   Wikidata; Q54798758
RX   CelloPub=CLPUB00416;
RX   DOI=10.4172/2324-9293.1000104;
RX   PubMed=1630814;
RX   PubMed=1764370;
RX   PubMed=3754176;
RX   PubMed=8026879;
RX   PubMed=8286197;
RX   PubMed=8426738;
RX   PubMed=10027410;
RX   PubMed=10408907;
RX   PubMed=11115575;
RX   PubMed=11169959;
RX   PubMed=12692724;
RX   PubMed=15126341;
RX   PubMed=15367885;
RX   PubMed=15688027;
RX   PubMed=18298655;
RX   PubMed=18380791;
RX   PubMed=20164919;
RX   PubMed=20418756;
RX   PubMed=21607521;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=25167228;
RX   PubMed=25485619;
RX   PubMed=25984343;
RX   PubMed=26216984;
RX   PubMed=27073551;
RX   PubMed=27259358;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 48-60 hours (PubMed=3754176); 48 hours (PubMed=25984343); ~48 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Heterozygous for BRAF p.Val487_Pro492delinsAla (c.1460_1474delGTGTAGGTGCTGTCA) (CCLE; Cosmic-CLP).
CC   Sequence variation: Homozygous for CDKN2A deletion (PubMed=11169959).
CC   Sequence variation: Has no KRAS mutation (PubMed=8026879; PubMed=11115575; PubMed=15367885).
CC   Sequence variation: Homozygous for SMAD4 deletion (PubMed=10408907; PubMed=15367885).
CC   Sequence variation: Homozygous for TP53 p.Tyr220Cys (c.659A>G) (PubMed=1630814; PubMed=8026879; PubMed=8426738; PubMed=11115575; PubMed=15367885; PubMed=21607521; CCLE; Cosmic-CLP).
CC   Omics: Transcriptome analysis.
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.55%; Native American=0%; East Asian, North=1.41%; East Asian, South=0%; South Asian=0%; European, North=69.25%; European, South=27.79% (PubMed=30894373).
CC   Caution: Additional TP53 mutation in c.793C>T indicated incorrectly in PubMed=1630814.
ST   Source(s): AddexBio; ATCC; Cosmic-CLP; DSMZ; ECACC; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 11
ST   D16S539: 9,11
ST   D18S51: 12
ST   D21S11: 29
ST   D3S1358: 14,16
ST   D5S818: 11
ST   D7S820: 10,13
ST   D8S1179: 13
ST   FGA: 20,21
ST   Penta D: 14
ST   Penta E: 12,14
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 14,18
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-07-19; Version: 28
RX   CelloPub=CLPUB00416;
RA   Oberlin L.;
RT   "Treatment of pancreatic carcinoma cell lines in vitro and vivo with a
RT   monoclonal antibody against the transferrin receptor.";
RL   Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany.
RX   DOI=10.4172/2324-9293.1000104;
RA   Wagenhauser M.U., Ruckert F., Niedergethmann M., Grutzmann R.,
RA   Saeger H.-D.;
RT   "Distribution of characteristic mutations in native ductal
RT   adenocarcinoma of the pancreas and pancreatic cancer cell lines.";
RL   Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013).
RX   PubMed=1630814;
RA   Ruggeri B., Zhang S.-Y., Caamano J., DiRado M., Flynn S.D.,
RA   Klein-Szanto A.J.P.;
RT   "Human pancreatic carcinomas and cell lines reveal frequent and
RT   multiple alterations in the p53 and Rb-1 tumor-suppressor genes.";
RL   Oncogene 7:1503-1511(1992).
RX   PubMed=1764370; DOI=10.1038/bjc.1991.467;
RA   Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C.,
RA   Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N.,
RA   Lane D.P., Lemoine N.R.;
RT   "Abnormalities of the p53 tumour suppressor gene in human pancreatic
RT   cancer.";
RL   Br. J. Cancer 64:1076-1082(1991).
RX   PubMed=3754176; DOI=10.3109/07357908609039823;
RA   Tan M.H., Nowak N.J., Loor R., Ochi H., Sandberg A.A., Lopez C.,
RA   Pickren J.W., Berjian R., Douglass H.O., Chu T.M.;
RT   "Characterization of a new primary human pancreatic tumor line.";
RL   Cancer Invest. 4:15-23(1986).
RX   PubMed=8026879; DOI=10.1002/ijc.2910580207;
RA   Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.;
RT   "Comparative analysis of mutations in the p53 and K-ras genes in
RT   pancreatic cancer.";
RL   Int. J. Cancer 58:185-191(1994).
RX   PubMed=8286197; DOI=10.1038/bjc.1994.24;
RA   Lohr M., Trautmann B., Gottler M., Peters S., Zauner I., Maillet B.,
RA   Kloppel G.;
RT   "Human ductal adenocarcinomas of the pancreas express extracellular
RT   matrix proteins.";
RL   Br. J. Cancer 69:144-151(1994).
RX   PubMed=8426738;
RA   Kalthoff H., Schmiegel W., Roeder C., Kasche D., Schmidt A., Lauer G.,
RA   Thiele H.-G., Honold G., Pantel K., Riethmuller G., Scherer E.,
RA   Maurer J., Maacke H., Deppert W.;
RT   "p53 and K-RAS alterations in pancreatic epithelial cell lesions.";
RL   Oncogene 8:289-298(1993).
RX   PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4;
RA   Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A.,
RA   Meltzer P.S., Ried T.;
RT   "Specific chromosomal aberrations and amplification of the AIB1
RT   nuclear receptor coactivator gene in pancreatic carcinomas.";
RL   Am. J. Pathol. 154:525-536(1999).
RX   PubMed=10408907; DOI=10.1016/S0304-3835(98)00380-2;
RA   Bartsch D., Barth P., Bastian D., Ramaswamy A., Gerdes B.,
RA   Chaloupka B., Deiss Y., Simon B., Schudy A.;
RT   "Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell
RT   lines than in primary pancreatic adenocarcinomas.";
RL   Cancer Lett. 139:43-49(1999).
RX   PubMed=11115575; DOI=10.3892/or.8.1.89;
RA   Sun C., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.;
RT   "Characterization of the mutations of the K-ras, p53, p16, and SMAD4
RT   genes in 15 human pancreatic cancer cell lines.";
RL   Oncol. Rep. 8:89-92(2001).
RX   PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C;
RA   Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M.,
RA   Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.;
RT   "Non-random chromosomal rearrangements in pancreatic cancer cell lines
RT   identified by spectral karyotyping.";
RL   Int. J. Cancer 91:350-358(2001).
RX   PubMed=12692724; DOI=10.1007/s00428-003-0784-4;
RA   Sipos B., Moser S., Kalthoff H., Torok V., Lohr M., Kloppel G.;
RT   "A comprehensive characterization of pancreatic ductal carcinoma cell
RT   lines: towards the establishment of an in vitro research platform.";
RL   Virchows Arch. 442:444-452(2003).
RX   PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159;
RA   Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L.,
RA   Veltman J.A., van Kessel A.G., Hoglund M.;
RT   "Genome-wide array-based comparative genomic hybridization reveals
RT   multiple amplification targets and novel homozygous deletions in
RT   pancreatic carcinoma cell lines.";
RL   Cancer Res. 64:3052-3059(2004).
RX   PubMed=15367885; DOI=10.1097/00006676-200410000-00004;
RA   Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M.,
RA   Hirohashi S.;
RT   "Orthotopic transplantation models of pancreatic adenocarcinoma
RT   derived from cell lines and primary tumors and displaying varying
RT   metastatic activity.";
RL   Pancreas 29:193-203(2004).
RX   PubMed=15688027; DOI=10.1038/sj.onc.1208383;
RA   Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H.,
RA   Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.;
RT   "Microarray analyses reveal strong influence of DNA copy number
RT   alterations on the transcriptional patterns in pancreatic cancer:
RT   implications for the interpretation of genomic amplifications.";
RL   Oncogene 24:1794-1801(2005).
RX   PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x;
RA   Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A.,
RA   Wellmann A., Braunschweig T., Lohr M., Jesenofsky R., Friess H.,
RA   Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F.,
RA   Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.;
RT   "Activation of Wnt signalling in stroma from pancreatic cancer
RT   identified by gene expression profiling.";
RL   J. Cell. Mol. Med. 12:2823-2835(2008).
RX   PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x;
RA   Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A.,
RA   Shiratori K., Hirohashi S., Inazawa J., Imoto I.;
RT   "Identification of SMURF1 as a possible target for 7q21.3-22.1
RT   amplification detected in a pancreatic cancer cell line by in-house
RT   array-based comparative genomic hybridization.";
RL   Cancer Sci. 99:986-994(2008).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963;
RA   Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J.,
RA   Scaife C.L., Firpo M.A., Mulvihill S.J.;
RT   "Phenotype and genotype of pancreatic cancer cell lines.";
RL   Pancreas 39:425-435(2010).
RX   PubMed=21607521; DOI=10.3892/or.1.6.1223;
RA   Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y.,
RA   Shimazoe T., Nawata H., Kono A.;
RT   "Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in
RT   human pancreatic cancer-derived cell-lines with different metastatic
RT   potential.";
RL   Oncol. Rep. 1:1223-1227(1994).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez F., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
RX   PubMed=25167228; DOI=10.1038/bjc.2014.475;
RA   Hamidi H., Lu M., Chau K., Anderson L., Fejzo M., Ginther C.,
RA   Linnartz R., Zubel A., Slamon D.J., Finn R.S.;
RT   "KRAS mutational subtype and copy number predict in vitro response of
RT   human pancreatic cancer cell lines to MEK inhibition.";
RL   Br. J. Cancer 111:1788-1801(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
RX   PubMed=26216984; DOI=10.1073/pnas.1501605112;
RA   Daemen A., Peterson D., Sahu N., McCord R., Du X., Liu B.,
RA   Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R.,
RA   Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.,
RA   Manning G., Settleman J., Hatzivassiliou G., Evangelista M.;
RT   "Metabolite profiling stratifies pancreatic ductal adenocarcinomas
RT   into subtypes with distinct sensitivities to metabolic inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
RX   PubMed=27073551; DOI=10.3892/ol.2016.4289;
RA   Fujiwara M., Kanayama K., Hirokawa Y.S., Shiraishi T.;
RT   "ASF-4-1 fibroblast-rich culture increases chemoresistance and mTOR
RT   expression of pancreatic cancer BxPC-3 cells at the invasive front in
RT   vitro, and promotes tumor growth and invasion in vivo.";
RL   Oncol. Lett. 11:2773-2779(2016).
RX   PubMed=27259358; DOI=10.1074/mcp.M116.058313;
RA   Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M.,
RA   Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K.,
RA   Biankin A.V., Wu J., Daly R.J.;
RT   "Resolution of novel pancreatic ductal adenocarcinoma subtypes by
RT   global phosphotyrosine profiling.";
RL   Mol. Cell. Proteomics 15:2671-2685(2016).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).